Heart failure: Management and prevention of heart failure based on current understanding of pathophysiological mechanisms

Interdisciplinary Concepts in Cardiovascular Health

Volumn , Issue , 2014, Pages 41-67

  Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin converting enzyme (ACE) inhibitors; Angiotensin II AT1 receptor blockers (ARBs); Brain natriuretic peptide (BNP); Ca2+ handling; Cardiac contractility; Cardiac remodeling; Cardiomyopathy; Endothelin; Force frequency relationship; Frank starling mechanism; LV ejection fraction; Myofilament Ca2+ sensitivity; Neurohumoral activation; Novel cardiotonic agents; Obstructive sleep apnea (OSA); Phosphodiesterase 3 (PDE3); Renin angiotensin aldosterone system (RAAS); Vasopressin; blockers

Indexed keywords

EID: 84955747882     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-01074-8_3     Document Type: Chapter

References (37)

1. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E, Heart Failure Clinical Research Network (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367(24):2296-2304
2. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH (2003) Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 63(6):525-534
3. Braunwald E, Bristow MR (2005) Congestive heart failure: fifty years of progress. Circulation 102(20 Suppl 4):IV14-IV23
4. Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA (1994) Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 72(2 Suppl):S36-S39
5. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodehng. J Am Coll Cardiol 35(3):569-582
6. Criteria Committee of the New York Heart Association (1942) Nomenclature and Criteria for Diagnosis of Diseases of the Heart. 4th ed. 8-9. NewYork, NewYork Heart Association
7. De Mello WC, Frohlich ED (2011) On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides 32(8):1774-1779
8. Edelmann F, Gelbrich G, Düngen HD, Fröhling S, Wachter R, Stahrenberg R, Binder L, Topper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Löffler M, Hasenfuss G, Halle M, Pieske B (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58(17):1780-1791
9. 2+ sensitizer. Circ J 72(12):1915-1925
10. Endoh M, Hori M (2006) Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother 7(16):2179-2202
11. Gassanov N, Biesenbach E, Caglayan E, Nia A, Fuhr U, Er F (2012) Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol 68(3):223-230
12. Georgiopoulou VV, Kalogeropoulos AP, Raggi P, Butler J (2010) Prevention, diagnosis, and treatment of hypertensive heart disease. Cardiol Clin 28(4):675-691
13. Hasenfuss G, Pieske B (2002) Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34(8):951-969
14. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K (2013) Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 9(2):99-111
15. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Failure 2006;12:e29
16. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society (2005) ACC/AHA 2005 guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112(12):e154-e235
17. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007-2018
18. Kasai T, Bradley TD (2011) Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol 57(2):119-127
19. Katz AM (2008) The “modern” view of heart failure: how did we get here? Circ Heart Fail 1(1):63-71
20. Katz AM (2011) Physiology of the heart, 5th edn. Lippincott Williams & Wilkins, Philadelphia
21. Katz AM, Konstam MA (2009) Heart failure: pathophysiology, molecular biology, and clinical management, 2nd edn. Lippincott Williams & Wilkins, Philadelphia
22. Layland J, Solaro RJ, Shah AM (2005) Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66(1):12-21
23. Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93(10):896-906
24. Morita H, Seidman J, Seidman CE (2005) Genetic causes of human heart failure. J Clin Invest 115(3):518-526
25. Movsesian MA (2000) Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin Investig Drugs 9(5):963-973
26. Neri Semeri GG, Boddi M, Coppo M, Chechi T, Zarone N, Moira M, Poggesi L, Margheri M, Simonetti I (1996) Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 94(8):1886-1893
27. Nomenclature and Criteria for Diagnosis of Diseases of the Heart. 4th ed. 8-9. New York, New York Heart Association.
28. Owan TE, Redfield MM (2005) Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47(5):320-332
29. Packer M (1992) Pathophysiology of chronic heart failure. Lancet 340(8811):88-92
30. Padeletti L, Innocenti L, Paoletti Perini A, Gronda E (2011) Arrhythmic complication in cardiorenal syndrome. Heart Fail Rev 16(6):569-573
31. 2 slope versus peak VO2 in systolic heart failure: a meta-analysis of the published literature. Am Heart J 160(6):1004-1014
32. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527-1539
33. Sabbah HN (2004) Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev 9(2):91-97
34. Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79(1):215-262
35. 2 AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol 51(4):529-533
36. Unger T, Li J (2004) The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 5(Suppl 1):S7-S10
37. van der Meer S, Zwerink M, van Brussel M, van der Valk P, Wajon E, van der Palen J (2012) Effect of outpatient exercise training programmes in patients with chronic heart failure: a systematic review. Eur J Prev Cardiol 19(4):795-803